NatureWise’s new chemical entity, NBM-MBX, received US Food and Drug Administration (FDA) approval on July 24th to proceed Phase I clinical trial.
NBM-MBX is an isoform-selective histone deacetylase 8 (HDAC 8) inhibitor. The high specificity produces less side effects than those of non-selective HDAC inhibitors.
NBM-BMX is so far the first HDAC8-specific inhibitor to enter human clinical trials in the world. Preclinical studies showed that NBM-BMX had low toxicity and could pass the blood-brain barrier. Its effect on glioblastoma multiforme is excellent. Glioblastoma is the most common and aggressive malignant brain tumor in adults. The overall survival of patients remains approximately 12 months only, and fewer than 3% to 5% patients surviving longer than five years after being diagnosed. Glioblastoma multiforme is a disease with high unmet medical need.
According to market analysis from GlobalData, the global market for glioblastoma has grown rapidly since 2014. By 2024, the market size will reach 3.3 billion US dollars, with an estimated CAGR of 17.4%.
It is obvious that the development of NBM-BMX has a great potential.